Capricor Therapeutics (NASDAQ:CAPR – Get Free Report) was upgraded by stock analysts at JonesTrading from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Wednesday, Benzinga reports. The firm currently has a $25.00 price objective on the biotechnology company’s stock. JonesTrading‘s price objective would indicate a potential upside of 127.03% from the company’s previous close.
Several other equities analysts also recently commented on the stock. Cantor Fitzgerald upgraded shares of Capricor Therapeutics from a “neutral” rating to an “overweight” rating in a research note on Friday, August 14th. HC Wainwright cut shares of Capricor Therapeutics from a “buy” rating to a “neutral” rating in a report on Monday, July 27th. Piper Sandler upgraded shares of Capricor Therapeutics from a “neutral” rating to an “overweight” rating in a research report on Tuesday, September 1st. Roth Capital cut Capricor Therapeutics from a “buy” rating to a “neutral” rating and set a $7.00 price target for the company. in a research note on Monday, July 27th. Finally, Wall Street Zen cut Capricor Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Saturday, August 1st. Five equities research analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $29.77.
Check Out Our Latest Stock Report on CAPR
Capricor Therapeutics Stock Up 24.1%
Shares of NASDAQ CAPR traded up $2.14 during mid-day trading on Wednesday, reaching $11.01. 8,156,062 shares of the company were exchanged, compared to its average volume of 3,184,348. The stock has a market capitalization of $640.23 million, a P/E ratio of -4.44 and a beta of 0.80. The company’s 50-day simple moving average is $8.06 and its 200-day simple moving average is $20.05. Capricor Therapeutics has a twelve month low of $2.96 and a twelve month high of $40.37.
Capricor Therapeutics (NASDAQ:CAPR – Get Free Report) last posted its earnings results on Tuesday, November 10th. The biotechnology company reported ($0.73) EPS for the quarter, missing the consensus estimate of ($0.44) by ($0.29). As a group, equities research analysts expect that Capricor Therapeutics will post -1.71 EPS for the current year.
Hedge Funds Weigh In On Capricor Therapeutics
Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Activest Wealth Management lifted its stake in shares of Capricor Therapeutics by 100.0% in the 3rd quarter. Activest Wealth Management now owns 4,000 shares of the biotechnology company’s stock valued at $38,000 after acquiring an additional 2,000 shares during the last quarter. KBC Group NV bought a new stake in Capricor Therapeutics during the 1st quarter worth $44,000. Russell Investments Group Ltd. increased its holdings in Capricor Therapeutics by 21.2% in the 3rd quarter. Russell Investments Group Ltd. now owns 17,326 shares of the biotechnology company’s stock worth $164,000 after purchasing an additional 3,036 shares in the last quarter. VestGen Advisors LLC acquired a new position in Capricor Therapeutics in the 3rd quarter worth about $191,000. Finally, SBI Securities Co. Ltd. increased its holdings in Capricor Therapeutics by 834.6% in the 3rd quarter. SBI Securities Co. Ltd. now owns 26,310 shares of the biotechnology company’s stock worth $249,000 after purchasing an additional 23,495 shares in the last quarter. Institutional investors own 21.68% of the company’s stock.
Key Capricor Therapeutics News
Here’s some of the latest news about CAPR:
- Positive Sentiment: Deramiocel cardiac data received an American Heart Association award, a recognition that may bolster interest in the treatment ahead of the FDA decision. Article: CAPR Stock Rises After Deramiocel Cardiac Data Wins American Heart Association Award Ahead Of FDA Decision
- Neutral Sentiment: Capricor outlined manufacturing validation work planned for 2027. This is relevant to potential commercialization, but also highlights that manufacturing readiness remains an execution consideration. Article: Capricor outlines 2027 manufacturing validation as Deramiocel BLA heads toward Nov. 22 PDUFA
- Negative Sentiment: Third-quarter loss widened: Capricor reported a loss of $0.73 per share, missing the $0.44 loss analysts expected. The company also cut its workforce by 10%, underscoring pressure to manage costs. Article: Capricor Therapeutics Q3 Net Loss Widens; Cuts Workforce by 10%
About Capricor Therapeutics
Capricor Therapeutics is a biotechnology company developing cell- and exosome-based therapies for serious diseases. Its research focuses on using these technologies to address conditions with limited treatment options. The company’s leading program is deramiocel, also known as CAP-1002, an investigational therapy made from donor-derived cardiac cells. Capricor is developing it for Duchenne muscular dystrophy, a rare genetic disorder that causes progressive muscle weakness. Capricor is also advancing an exosome-based technology platform for potential therapeutic applications.
See Also
- Five stocks we like better than Capricor Therapeutics
- Keeping AI Cool: AAON Rides the AI Heatwave to Record Growth
- AST SpaceMobile Has a New Rocket Plan, But Its Cash-Burn Problem Isn’t Going Away
- Powering Up the Moon: Redwire’s $40 Million NASA Award
- Can Constellation Energy’s Contracts Power a Stock Rebound?
Receive News & Ratings for Capricor Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Capricor Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
